Jefferies Defends Epizyme (EPZM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts EPZM Hot Sheet
Price: $1.47 --0%
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 33
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 33
Join SI Premium – FREE
Jefferies analyst Michael Yee defends Epizyme (NASDAQ: EPZM) following weakness after the FDA briefing documents.
- 'Briefing Documents Read Mixed But We Would Buy on Weakness'
The firm reiterated a Buy rating and $21.00 price target on EPZM.
For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.
Shares of Epizyme closed at $17.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Adds Positive Catalyst Watch on Tango Therapeutics Inc. (TNGX)
- Ladenburg Thalmann Starts American Outdoor Brands Inc. (AOUT) at Buy
- H.C. Wainwright Reiterates Buy Rating on Envoy Medical (COCH)
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
Jefferies & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
